Roanna Ruiz
Stock Analyst at Leerink Partners
(0.85)
# 3,913
Out of 4,996 analysts
65
Total ratings
34.15%
Success rate
-14.44%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $9 | $8.18 | +10.02% | 7 | Aug 19, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $2.74 | +155.47% | 1 | Apr 28, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $11.30 | +59.29% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $1.40 | -28.57% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $5.49 | +264.30% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $9.80 | +175.51% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $5.99 | +117.03% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $5.54 | +152.71% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $432.66 | -23.73% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $50.40 | +15.08% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $83.87 | -70.19% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $7.90 | +520.25% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $5.65 | +130.09% | 7 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $2.93 | +104.78% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $28.50 | -33.33% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $50.61 | +137.11% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $9.79 | +410.73% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $16.00 | +150.00% | 6 | Oct 19, 2022 |
Xeris Biopharma Holdings
Aug 19, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $8.18
Upside: +10.02%
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $2.74
Upside: +155.47%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $11.30
Upside: +59.29%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $1.40
Upside: -28.57%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $5.49
Upside: +264.30%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $9.80
Upside: +175.51%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $5.99
Upside: +117.03%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $5.54
Upside: +152.71%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $432.66
Upside: -23.73%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $50.40
Upside: +15.08%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $83.87
Upside: -70.19%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $7.90
Upside: +520.25%
Jan 27, 2023
Maintains: Outperform
Price Target: $12 → $13
Current: $5.65
Upside: +130.09%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $2.93
Upside: +104.78%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $28.50
Upside: -33.33%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $50.61
Upside: +137.11%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $9.79
Upside: +410.73%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $16.00
Upside: +150.00%